Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children
dc.contributor.author | Madani, Shailender | en_US |
dc.contributor.author | Kauffman, Ralph | en_US |
dc.contributor.author | Simpson, Pippa | en_US |
dc.contributor.author | Lehr, Victoria Tutag | en_US |
dc.contributor.author | Lai, Mary Lieh | en_US |
dc.contributor.author | Sarniak, Ashok | en_US |
dc.contributor.author | Tolia, Vasundhara | en_US |
dc.date.accessioned | 2014-02-11T17:57:09Z | |
dc.date.available | 2015-04-01T19:59:07Z | en_US |
dc.date.issued | 2014-02 | en_US |
dc.identifier.citation | Madani, Shailender; Kauffman, Ralph; Simpson, Pippa; Lehr, Victoria Tutag; Lai, Mary Lieh; Sarniak, Ashok; Tolia, Vasundhara (2014). "Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children." The Journal of Clinical Pharmacology 54(2): 201-205. | en_US |
dc.identifier.issn | 0091-2700 | en_US |
dc.identifier.issn | 1552-4604 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/102678 | |
dc.description.abstract | To characterize and compare acid suppression (pharmacodynamics) and pharmacokinetics of IV famotidine and ranitidine in critically ill children at risk for stress gastritis. Single‐blind, randomized study in PICU patients 6 months to 18 years requiring mechanical ventilation with continuous gastric pH monitoring, randomized to IV famotidine 12 mg/m 2 or ranitidine 60 mg/m 2 when gastric pH < 4.0 >1 hour with serial blood sampling following first dose. Twenty‐four children randomized to either famotidine (n = 12) or ranitidine (n = 12). Sixteen out of twenty‐four completed both PK and PD study arms (7/12 famotidine; 4.7 ± 3.4 years; 9/12 ranitidine; 6.6 ± 4.7 years; p = 0.38). Time to gastric pH 4.0 and total time pH above 4.0 similar with no difference in pH at 6 and 12 hours ( p > 0.2). No difference between drugs in clearance, volume of distribution and half‐life ( p > 0.05). Ratio of AUC pH to AUC drug concentration 0–12 hours after first dose was significantly greater for famotidine (0.06849 ± 0.01460 SD) than ranitidine (0.02453 ± 0.01448; p < 0.001) demonstrating greater potency of famotidine. pH lowering efficacy of both drugs is similar. Greater potency of famotidine may offer clinical advantage due to lower drug exposure and less frequent dosing to achieve same pH lowering effect. | en_US |
dc.publisher | Nottingham University Press | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Famotidine | en_US |
dc.subject.other | Ranitidine | en_US |
dc.subject.other | Pediatric Intensive Care Unit | en_US |
dc.subject.other | Pharmacokinetics | en_US |
dc.subject.other | Pharmacodynamics | en_US |
dc.subject.other | Gastric Acid Suppression | en_US |
dc.title | Pharmacokinetics and pharmacodynamics of famotidine and ranitidine in critically ill children | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pediatrics | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/102678/1/jcph219.pdf | |
dc.identifier.doi | 10.1002/jcph.219 | en_US |
dc.identifier.source | The Journal of Clinical Pharmacology | en_US |
dc.identifier.citedreference | Maples HD, James LP, Stowe CD, et al. Famotidine disposition in children with adolescents with chronic renal insufficiency. J Clin Pharmacol. 2003; 43: 7 – 14. | en_US |
dc.identifier.citedreference | Deerojanawong J, Peongsujarit D, Vivatvakin B, Prapphal N. Incidence and risk factors of upper gastrointestinal bleeding in mechanically ventilated children. Pediatr Crit Care Med. 2009; 10 ( 1 ): 91 – 95. doi: 10.1097/PCC.0b013e3181936a37 | en_US |
dc.identifier.citedreference | Reveiz L, Guerrero‐Lozano R, Camacho A, Yara L, Mosquera PA. Stress ulcer, gastritis, and gastrointestinal bleeding prophylaxis in critically ill pediatric patients: a systematic review. Pediatr Crit Care Med. 2010; 11 ( 1 ): 124 – 132. doi: 10.1097/PCC.0b013e3181b80e70 | en_US |
dc.identifier.citedreference | Ali T, Harty R. Stress induced ulcer bleeding in critically ill patients. Gastroenterol Clin N Am. 2009; 38: 245 – 265. | en_US |
dc.identifier.citedreference | American Society of Health‐System Pharmacists. ASHP therapeutic guidelines on stress ulcer prophylaxis. Am J Health Syst Pharm. 1999; 56: 347 – 379. | en_US |
dc.identifier.citedreference | Cook DJ, Witt LG, Cook RJ, et al. Stress ulcer prophylaxis in the critically ill: a meta‐analysis. Am J Med. 1991; 91: 519 – 527. | en_US |
dc.identifier.citedreference | Chin TWF, MacLeod SM, Fenje P, Baltodano A, Edmonds JF, Soldin SJ. Pharmacokinetics of cimetidine in critically‐ill children. Pediatr Pharmacol. 1983; 2: 285 – 292. | en_US |
dc.identifier.citedreference | Lugo RA, Harrison AM, Cash J, et al. Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children. Crit Care Med. 2001; 29 ( 4 ): 759 – 764. | en_US |
dc.identifier.citedreference | James LP, Kearns GL. Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients. Clin Pharmacokinet. 1996; 31 ( 2 ) 103 – 110. | en_US |
dc.identifier.citedreference | Kraus G, Krishna DR, Chmelarsch D, Schmid M, Klotz U. Famotidine, pharmacokinetic properties and suppression of acid secretion in pediatric patients following cardiac surgery. Clin Pharmacokinet. 1990; 18 ( 1 ): 77 – 81. | en_US |
dc.identifier.citedreference | Wenning LA, Murphy MG, James LP, et al. Pharmacokinetics of famotidine in infants. Clin Pharmacokinet. 2005; 44 ( 4 ): 395 – 406. | en_US |
dc.identifier.citedreference | Du W, Tutag Lehr V, Caverly M, Kelm L, Lieh‐Lai M. Adverse drug reactions in pediatric intensive care unit. J Clin Pharmacol. 2013; 53 ( 5 ): 567 – 573. | en_US |
dc.identifier.citedreference | Choonara I, Rieder MJ. Drug Toxicity and Adverse Drug Reactions in Children—A Brief Historical Review. Nottingham, England: Nottingham University Press; 2004. | en_US |
dc.identifier.citedreference | Leeder JS. Developmental pediatric pharmacogenomics. Pharmacogenomics. 2003; 4 ( 3 ): 331 – 341. | en_US |
dc.identifier.citedreference | Ziemniak JA, Assael BM, Padoan R, Schentag JJ. The bioavailability and pharmacokinetics of cimetidine and its metabolites in juvenile cystic fibrosis patient: age‐related differences as compared to adults. Eur J Clin Pharmacol. 1984; 26: 183 – 189. | en_US |
dc.identifier.citedreference | Treem WR, Davis PM, Hyams JS. Suppression of gastric acid secretion by intravenous use of famotidine in children. J Pediatr. 1991; 118 ( 5 ): 812 – 816. | en_US |
dc.identifier.citedreference | Harrison AM, Lugo RA, Vernon DD. Gastric pH control in critically ill children receiving iv ranitidine. Crit Care Med. 1998; 26: 1433 – 1436. | en_US |
dc.identifier.citedreference | Hawwa AF, Westwood PM, Collier PS, et al. Prophylactic ranitidine treatment in critically ill children—a population pharmacokinetic study. Br J Pharmacol. 2013; 75 ( 5 ): 1265 – 1276. | en_US |
dc.identifier.citedreference | Wincek WC. Analytical methodology for quantitation of Famotidine and H 2 receptor blockers in plasma and urine. J Chromotogr. 1985; 338: 438 – 443. | en_US |
dc.identifier.citedreference | Karnes HT, Opong‐Mensah K, Farthing D, Beightol LA. Automated solid phase extraction and high performance liquid chromatographic determination of rantidine from urine, plasma and peritoneal dialysate. J Chromatogr. 1987; 422: 165 – 173. | en_US |
dc.identifier.citedreference | Kuitunen A, Vento A, Suojaranta‐Ylinen R, Pettila V. Acute renal failure after cardiac surgery: evaluation of the RIFLE classification. Ann Thorac Surg. 2006; 81: 542 – 546. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.